TESARO Initiates Phase 3 Trial of Niraparib for Treatment of Patients With Ovarian Cancer
July 23, 2013 at 07:17 AM EDT
TESARO, Inc. (Nasdaq: TSRO ), an oncology-focused biopharmaceutical company, today announced that it has initiated patient enrollment in a Phase 3 trial of niraparib, an inhibitor of poly ADP-ribose polymerase (PARP), for the treatment of ovarian cancer. This trial, referred to as NOVA, will evaluate a single daily 300
